SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : QLT PhotoTherapeutics (QLTI)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Archangel who wrote (997)9/20/2000 2:41:12 PM
From: Ian@SI  Read Replies (1) of 1321
 
Elayne Wandler gave an informed investors presentation today.

Replay should be available by now for those who missed the live version.

During the Q&A, it didn't seem as if QLT is in any rush to fill the CFO spot. Their finances are in order with $177M US in the bank; profitability from Visudyne sales; and the good progress in automating their financial processes. And she seems to be doing a good job handling the Analcyst community.

Also in reponse to a Skin Cancer trial Q, she advised that results were good; data will be released in about a month perhaps a little less; because of the photofrin sale and its impact on their Cancer capabilities, decisions will have to be made re selling it, going it alone or seeking a new partner.

And finally, sounds like the Psoriasis Phase II also produced good results using Verteporfin. Another Phase II trial using their new drug, QLT 0074, will probably be done.

And another little gem: From one of her comments in the body of the presentation, it appears that the wavelength of laser light that activates Visudyne is different from the wavelengths that activate other drugs under development by potential competitors. To the extent that this is true, it would seem to me that QLT will have established an overwhelming competitive advantage.

They've saturated the retinal specialists with Lasers and training that is applicable to Visudyne alone. With the headstart that QLT has established this sounds like a nearly insurmountable barrier to competition.

Replay available at informedinvestors.com
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News